Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesMyeloproliferative Diseases and Disorders, Poorly Differentiated NeoplasmsDRG 825-lymphoma-and-non-acute-leukemia-with-other-procedures-without-cc-mcc
    Ask Trek AI about this page

    Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    DRG 825 includes admissions for lymphoma and non-acute leukemia with other procedures when no Complication or Comorbidity or Major Complication or Comorbidity is present; it addresses cases with operative intervention but lower documented clinical severity. This grouping matters for inpatient reimbursement because it assigns the Centers for Medicare & Medicaid Services payment relative to expected resource use for these moderate-severity surgical admissions.

    Customize your policy alerts

    Sign up for drg 825 policy alerts

    Get alerted when payer policies referencing 825 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 825 Overview

    DRG 825 covers inpatient admissions for patients with lymphoma and non-acute leukemia who undergo other procedures without a Complication or Comorbidity or Major Complication or Comorbidity. This category groups cases where the principal diagnosis is a lymphoid malignancy and a secondary operative procedure is performed that does not meet higher-severity grouping criteria. It matters for Centers for Medicare & Medicaid Services payment because it defines a specific payment weight reflecting average resource use for these less complex procedural admissions. Accurate coding of diagnoses and procedures determines inclusion in this Diagnosis-Related Group and affects Medicare inpatient reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Trials evaluating peri-procedural optimization and complication reduction for patients with lymphoma or chronic (non-acute) leukemia undergoing other invasive procedures (such as biopsy, central line placement, or minor surgical interventions). These studies enroll inpatients with active lymphoma or indolent/non-acute leukemia who require procedural interventions to characterize bleeding, infection, and wound-healing risks, and test standardized preoperative assessment and prophylaxis protocols. Results are highly relevant to providers for reducing procedure-related morbidity and to payers because lower complication rates can shorten length of stay and reduce downstream costs.
    • Comparative effectiveness studies of chemoimmunotherapy sequencing or supportive-care bundles in the non-acute leukemia/lymphoma inpatient population receiving non-definitive procedures. These trials compare timing and sequencing of systemic therapy relative to procedures (for example deferring versus initiating certain systemic agents around invasive procedures) and assess short-term outcomes such as transfusion needs, febrile neutropenia, and inpatient resource utilization. Findings inform clinicians about balancing disease control with procedural safety and help payers evaluate which care pathways yield better value by reducing readmissions and intensive-support use.
    • Post-discharge outcomes and care coordination studies focused on transitions from inpatient stays where other procedures were performed to outpatient oncology management. These observational or pragmatic interventional studies follow patients with lymphoma or chronic leukemia after discharge to measure adherence to follow-up, delays in planned therapy, rates of readmission for infection or complication, and patient-reported functional recovery. This research addresses gaps in continuity of care that affect clinical outcomes and is pertinent to payers and health systems aiming to improve readmission rates, optimize post-acute resource allocation, and align reimbursement with quality transitions.

    Related Codes

    820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

    824-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-CC

    Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

    826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    828-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    830-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 27

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.